These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 11559551)

  • 1. In vitro targeted killing of prostate tumor cells by a synthetic amoebapore helix 3 peptide modified with two gamma-linked glutamate residues at the COOH terminus.
    Warren P; Li L; Song W; Holle E; Wei Y; Wagner T; Yu X
    Cancer Res; 2001 Sep; 61(18):6783-7. PubMed ID: 11559551
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vivo targeted killing of prostate tumor cells by a synthetic amoebapore helix 3 peptide modified with two γ-linked glutamate residues at the COOH terminus.
    Holle L; Song W; Holle E; Nilsson J; Wei Y; Li J; Wagner TE; Yu X
    Mol Med Rep; 2009; 2(3):399-403. PubMed ID: 21475841
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cytolytic and antibacterial activity of synthetic peptides derived from amoebapore, the pore-forming peptide of Entamoeba histolytica.
    Leippe M; Andrä J; Müller-Eberhard HJ
    Proc Natl Acad Sci U S A; 1994 Mar; 91(7):2602-6. PubMed ID: 8146160
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of methotrexate-based peptide substrates to characterize the substrate specificity of prostate-specific membrane antigen (PSMA).
    Mhaka A; Gady AM; Rosen DM; Lo KM; Gillies SD; Denmeade SR
    Cancer Biol Ther; 2004 Jun; 3(6):551-8. PubMed ID: 15044850
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prostate-specific membrane antigen: a novel folate hydrolase in human prostatic carcinoma cells.
    Pinto JT; Suffoletto BP; Berzin TM; Qiao CH; Lin S; Tong WP; May F; Mukherjee B; Heston WD
    Clin Cancer Res; 1996 Sep; 2(9):1445-51. PubMed ID: 9816319
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of carbohydrate moieties on the folate hydrolysis activity of the prostate specific membrane antigen.
    Ghosh A; Heston WD
    Prostate; 2003 Oct; 57(2):140-51. PubMed ID: 12949938
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Alterations of prostate biomarker expression and testosterone utilization in human LNCaP prostatic carcinoma cells by garlic-derived S-allylmercaptocysteine.
    Pinto JT; Qiao C; Xing J; Suffoletto BP; Schubert KB; Rivlin RS; Huryk RF; Bacich DJ; Heston WD
    Prostate; 2000 Dec; 45(4):304-14. PubMed ID: 11102955
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterization and glutamyl preferring carboxypeptidase function of prostate specific membrane antigen: a novel folate hydrolase.
    Heston WD
    Urology; 1997 Mar; 49(3A Suppl):104-12. PubMed ID: 9123729
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification and characterization of nuclease-stabilized RNA molecules that bind human prostate cancer cells via the prostate-specific membrane antigen.
    Lupold SE; Hicke BJ; Lin Y; Coffey DS
    Cancer Res; 2002 Jul; 62(14):4029-33. PubMed ID: 12124337
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of prostate-specific membrane antigen (PSMA)-positive tumor growth by vaccination with either full-length or the C-terminal end of PSMA.
    Kuratsukuri K; Sone T; Wang CY; Nishisaka N; Jones RF; Haas GP
    Int J Cancer; 2002 Nov; 102(3):244-9. PubMed ID: 12397643
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro characterization of radiolabeled monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen.
    Smith-Jones PM; Vallabahajosula S; Goldsmith SJ; Navarro V; Hunter CJ; Bastidas D; Bander NH
    Cancer Res; 2000 Sep; 60(18):5237-43. PubMed ID: 11016653
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Five different anti-prostate-specific membrane antigen (PSMA) antibodies confirm PSMA expression in tumor-associated neovasculature.
    Chang SS; Reuter VE; Heston WD; Bander NH; Grauer LS; Gaudin PB
    Cancer Res; 1999 Jul; 59(13):3192-8. PubMed ID: 10397265
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A dimeric peptide that binds selectively to prostate-specific membrane antigen and inhibits its enzymatic activity.
    Aggarwal S; Singh P; Topaloglu O; Isaacs JT; Denmeade SR
    Cancer Res; 2006 Sep; 66(18):9171-7. PubMed ID: 16982760
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Novel ¹¹¹In-Labeled Anti-Prostate-Specific Membrane Antigen Nanobody for Targeted SPECT/CT Imaging of Prostate Cancer.
    Chatalic KL; Veldhoven-Zweistra J; Bolkestein M; Hoeben S; Koning GA; Boerman OC; de Jong M; van Weerden WM
    J Nucl Med; 2015 Jul; 56(7):1094-9. PubMed ID: 25977460
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Shortened amoebapore analogs with enhanced antibacterial and cytolytic activity.
    Andrä J; Berninghausen O; Wülfken J; Leippe M
    FEBS Lett; 1996 Apr; 385(1-2):96-100. PubMed ID: 8641476
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Isolation and characterization of monoclonal antibodies specific for protein conformational epitopes present in prostate-specific membrane antigen (PSMA).
    Tino WT; Huber MJ; Lake TP; Greene TG; Murphy GP; Holmes EH
    Hybridoma; 2000 Jun; 19(3):249-57. PubMed ID: 10952413
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Screening of HLA-A24-restricted epitope peptides from prostate-specific membrane antigen that induce specific antitumor cytotoxic T lymphocytes.
    Horiguchi Y; Nukaya I; Okazawa K; Kawashima I; Fikes J; Sette A; Tachibana M; Takesako K; Murai M
    Clin Cancer Res; 2002 Dec; 8(12):3885-92. PubMed ID: 12473604
    [TBL] [Abstract][Full Text] [Related]  

  • 18. DNA fusion gene vaccines induce cytotoxic T-cell attack on naturally processed peptides of human prostate-specific membrane antigen.
    Vittes GE; Harden EL; Ottensmeier CH; Rice J; Stevenson FK
    Eur J Immunol; 2011 Aug; 41(8):2447-56. PubMed ID: 21604260
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression of prostate specific membrane antigen and three alternatively spliced variants of PSMA in prostate cancer patients.
    Schmittgen TD; Teske S; Vessella RL; True LD; Zakrajsek BA
    Int J Cancer; 2003 Nov; 107(2):323-9. PubMed ID: 12949815
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A new generation of monoclonal and recombinant antibodies against cell-adherent prostate specific membrane antigen for diagnostic and therapeutic targeting of prostate cancer.
    Elsässer-Beile U; Wolf P; Gierschner D; Bühler P; Schultze-Seemann W; Wetterauer U
    Prostate; 2006 Sep; 66(13):1359-70. PubMed ID: 16894535
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.